FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Phase 1

Completed

Conditions: Philadelphia Positive Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Childhood Acute Lymphoblastic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Chronic Myelogenous Leukemia
Relapsing Chronic Myelogenous Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: nilotinib
Drug: imatinib mesylate
Other: pharmacological study

First Posted Date: 2008-06-20

Last Posted Date: 2017-08-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00702403

Locations: 🇺🇸
H Lee Moffitt Cancer Center and Research Institute Phase 2 Consortium, Tampa, Florida, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Stanford University Hospitals and Clinics, Stanford, California, United States

and more 2 locations

Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)

Interventions: Drug: gemtuzumab ozogamicin
Drug: vorinostat
Other: laboratory biomarker analysis

First Posted Date: 2008-05-07

Last Posted Date: 2017-06-01

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00673153

Locations: 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Phase 1

Terminated

Conditions: Gliosarcoma
Glioblastoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carmustine
Biological: Filgrastim
Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: O6-Benzylguanine
Drug: Plerixafor
Radiation: Proton Beam Radiation Therapy
Drug: Temozolomide

First Posted Date: 2008-04-30

Last Posted Date: 2022-05-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT00669669

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effect of Exercise on Sex Hormones in Postmenopausal Women

Phase 2

Completed

Conditions: Breast Cancer Prevention

Interventions: Behavioral: Exercise

First Posted Date: 2008-04-29

Last Posted Date: 2012-11-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 173

Registration Number: NCT00668174

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Effect of Exercise on Biomarkers of Colon Cancer Risk

Phase 2

Completed

Conditions: Colon Cancer Prevention

Interventions: Behavioral: Exercise

First Posted Date: 2008-04-29

Last Posted Date: 2012-11-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 202

Registration Number: NCT00668161

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Improving Outcomes Assessment in Chronic GVHD

Active, not recruiting

Conditions: Chronic Graft Versus Host Disease

First Posted Date: 2008-03-18

Last Posted Date: 2024-03-26

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 601

Registration Number: NCT00637689

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Phase 1

Completed

Conditions: Systemic Scleroderma
Severe Systemic Sclerosis

Interventions: Drug: fludarabine phosphate
Drug: Mycophenolic Acid
Drug: tacrolimus
Radiation: total-body irradiation
Procedure: bone marrow transplantation
Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation
Procedure: quality-of-life assessment
Other: laboratory biomarker analysis
Other: flow cytometry
Procedure: biopsy

First Posted Date: 2008-02-25

Last Posted Date: 2018-06-04

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00622895

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States